Lupin Partners with TB Alliance to Advance Telacebec for TB, Leprosy and Buruli Ulcer
Mumbai: Pharma major Lupin Limited has announced a strategic collaboration with TB Alliance, a nonprofit drug developer, to advance the clinical development and commercialization of the investigational drug Telacebec (formerly Q203), targeting multiple mycobacterial diseases including tuberculosis (TB), leprosy, and Buruli ulcer.
Under the collaboration, TB Alliance will continue to lead the development process, while Lupin will contribute its expertise in global manufacturing, regulatory affairs, and supply chain management to ensure equitable global access to Telacebec. The partnership aims to expand treatment options for patients affected by these diseases worldwide.
Commenting on the collaboration, Ramesh Swaminathan, Executive Director, Global CFO, and Head of IT and API Plus SBU, Lupin, said:
“This collaboration with TB Alliance underscores Lupin’s enduring commitment to improving patient outcomes in areas of significant unmet medical need. By leveraging our manufacturing scale and global distribution capabilities alongside TB Alliance’s deep expertise in drug development, we aim to enable timely and equitable access to Telacebec and contribute meaningfully to the global fight against tuberculosis, leprosy, and Buruli ulcer.”
Mel Spigelman, MD, President and CEO, TB Alliance, added:
“Telacebec represents the kind of scientific innovation that has the potential to transform treatment for diseases that have long been neglected. By partnering with Lupin, we are combining deep scientific expertise with global Chemistry, Manufacturing and Controls and access capabilities to help move this promising compound forward as quickly and responsibly as possible, with the ultimate goal of delivering better treatment options to people affected by tuberculosis, leprosy, and Buruli ulcer around the world.”
Lupin Limited, headquartered in Mumbai, India, specializes in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients, with strong positions in India and the U.S. across multiple therapy areas including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, CNS, and women’s health. Lupin operates 15 manufacturing sites and 7 research centers worldwide, with a workforce of over 24,000 professionals. Its subsidiaries include Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
TB Alliance is a not-for-profit organization committed to developing faster-acting and affordable treatments for TB and related mycobacterial diseases such as leprosy and Buruli ulcer. Through global partnerships and innovative science, TB Alliance ensures equitable access to improved TB cures. Its work is supported by major global partners including Gates Foundation, US NIH (NCATS & NIAID), Unitaid, UK FCDO, Germany BMFTR, Australia DFAT, South Korea Global Disease Eradication Fund, and MedAccess.
